Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice

Hepatology

Volumn 60, Issue 2, 2014, Pages 531-544

  Locatelli, Irene ^a   Sutti, Salvatore ^a   Jindal, Aastha ^a   Vacchiano, Marco ^a   Bozzola, Cristina ^a   Reutelingsperger, Chris ^b   Kusters, Dennis ^b   Bena, Stefania ^c   Parola, Maurizio ^d   Paternostro, Claudia ^d   Bugianesi, Elisabetta ^e   Mcarthur, Simon ^c   Albano, Emanuele ^a   Perretti, Mauro ^c  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; GALECTIN 3; INTERLEUKIN 10; LIPOCORTIN 1; METHIONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEEDING; FIBROGENESIS; HEPATITIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER BIOPSY; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STIMULATION; WILD TYPE;

ANIMALS; ANNEXIN A1; CHOLINE DEFICIENCY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; HEPATITIS; HUMANS; LIVER CIRRHOSIS; MACROPHAGES; MALE; METHIONINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY;

EID: 84904664196     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27141     Document Type: Article

References (44)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350.
2. Marra F, Gastaldelli A, Svegliati-Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81.
3. Tilg H, Mochen AR. Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52:1836-1846.
4. Ariel A, Timor O. Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis. J Pathol 2013;229:250-263.
5. Ortega-Gómez A, Perretti M, Soehnlein O. Resolution of inflammation: an integrated view. EMBO Mol Med 2013;5:661-674.
6. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009;9:62-70.
7. Gavins FNE, Hickey M. Annexin A1 and the regulation of innate and adaptive immunity. Front Immunol 2012;3:354.
8. Martin GR, Perretti M, Flower RJ, Wallace JL. Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol 2008;294:G764-G769.
9. Leoni G, Alam A, Neumann PA, Lambeth JD, Cheng G, McCoy J, et al. Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair. J Clin Invest 2013;123:443-454.
10. Damazo AS, Sampaio AL, Nakata CM, Flower RJ, Perretti M, Oliani SM. Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis. BMC Immunol 2011;12:59.
11. Kosicka A, Cunliffe AD, Mackenzie R, Zariwala MG, Perretti M, Flower RJ, Renshaw D. Attenuation of plasma annexin A1 in human obesity. FASEB J 2013;27:368-378.
12. Akasheh RT, Pini M, Pang J, Fantuzzi G. Increased adiposity in annexin A1-deficient mice. PLoS One 2013;8:e82608.
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
14. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010;184:2611-2619.
15. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond) 2012;122:545-553.
16. Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, et al. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc Natl Acad Sci U S A 2013;110:18232-18237.
17. Li Y, Cai L, Wang H, Wu P, Gu W, Chen Y, et al. Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 2011;30:3887-3899.
18. Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 2011;54:975-983.
19. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006;103:5060-5065.
20. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol 2012;3:56.
21. Larter CZ, Yeh MM. Animal model of NASH: getting both pathology and metabolic contest right. J Gastroenterol Hepatol 2008;23:1635-1648.
22. Yang YH, Aeberli D, Dacumos A, Xue JR, Morand EF. Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol 2009;183:1435-1445.
23. Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 2002;8:1296-1302.
24. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010;107:1660-1665.
25. Soehnlein O, Zernecke A, Eriksson EE, Rothfuchs AG, Pham CT, Herwald H, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008;112:1461-1471.
26. Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl peptide receptor agonists. Pharmacol Ther 2010;127:175-188.
27. Souza DG, Fagundes CT, Amaral FA, Cisalpino D, Sousa LP, Vieira AT, et al. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007;179:8533-8543.
28. Lange C, Starrett DJ, Goetsch J, Gerke V, Rescher U. Transcriptional profiling of human monocytes reveals complex changes in the expression pattern of inflammatory-related genes in response to the annexinA1-derived peptide Ac1-25. J Leukoc Biol 2007;82:1592-1604.
29. Brunt EM. Pathology of non-alcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010;7:195-203.
30. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 2012;61:416-426.
31. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol 2012;302:G1310-G1321.
32. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-171.
33. Dragomir AC, Sun R, Choi H, Laskin JD, Laskin DL. Role of galectin-3 in classical and alternative macrophage activation in the liver following acetaminophen intoxication. J Immunol 2012;189:5934-5941.
34. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology 2012;55:1954-1964.
35. Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, Scott F, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol 2012;302:G439-G444.
36. Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, Tabuchi Y, Tsuneyama K. Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. ScientificWorldJournal 2012;2012:959824.
37. Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, Cui ZG, et al. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 2006;210:469-477.
38. Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ, et al. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS One 2013;8:e57915.
39. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, et al. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 2013;62:1932-1944.
40. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-298.
41. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67-75.
42. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, Friedman SL. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013;8:e75361.
43. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 2013;8:e834811.
44. Dalli J, Consalvo AP, Ray V, Di Filippo C, D'Amico M, Mehta N, Perretti M. Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J Immunol 2013;190:6478-6487.